In vivo, the silent IGF2R MSCs were utilized to treat the D12 rats, found that this inhibited the increase of CCA, alleviated the tumor burden and injury of liver, which caused by MSCs. This evidence concerns the gene IGF2R and cholangiocarcinoma.